PMID:
J Neurosurg Sci. 2020 Jan 20. Epub 2020 Jan 20. PMID: 31957998
Abstract Title:
Supplementary management with Pycnogenol® in Parkinson's disease to prevent cognitive impairment.
Abstract:
BACKGROUND: The aim of this registry study in patients with Parkinson's Disease (PD) in treatment, was to evaluate the effects of Pycnogenol® supplementation on some accessory symptoms and cognitive functions (COFU).METHODS: The registry included 43 PD patients who had been diagnosed at least one year before the registry. The condition was considered 'mild', with minimal progression. The management for these patients was a monotherapy using carbidopa/levodopa (standard management; SM). Supplementary Pycnogenol® was used at 150 mg/day for 4 weeks. The neurological management was not affected.RESULTS: Tolerability and safety were very good; the two registry groups were comparable with comparable symptoms at baseline. The most disabling symptoms were considered tremor, bradychinesia, alterations in COFU, rigidity and speech changes. All symptoms were rated as mild-to-moderate. After 4 weeks, these target symptoms were attenuated with the supplement more than with the SM only (p
Health Time 